Market
J&J raises FY26 outlook following positive Q2
Johnson & Johnson raised its fiscal 2026 outlook following strong second-quarter results, with MedTech contributing $8.9 billion of the division's $25.3 billion in total Q2 revenues. Growth was driven in part by its cardiovascular portfolio, including the Shockwave IVL lithotripsy system.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network